2025-10-23 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the data you provided. The report will be in English and include the requested numerical summaries and analysis.

**Teladoc Health Inc. (TDOC) Analysis**

Teladoc Health Inc. is a telehealth company that provides virtual healthcare services.

**1. Performance vs. S&P 500 (VOO)**

*   **TDOC Cumulative Return:** -58.34%
*   **VOO Cumulative Return:** 100.13%
*   **Absolute Divergence (TDOC - VOO):** -158.47%
*   **Divergence Range:** Max: 312.6, Min: -162.5, Current: -157.1
*   **Relative Divergence:** 1.1

**Analysis:** TDOC has significantly underperformed the S&P 500. The cumulative return difference is substantial. The relative divergence of 1.1 suggests that the current divergence is near the lower end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha    | Beta   | Cap(B) |
| :----------- | :------- | :------- | :------- | :----- | :----- |
| 2015-2017  | 77.0%    | 70.4%    | 51.0%    | -0.1   | 5.9    |
| 2016-2018  | 101.0%   | 69.4%    | 86.0%    | -0.1   | 8.4    |
| 2017-2019  | 141.0%   | 73.8%    | 118.0%   | 0.3    | 14.2   |
| 2018-2020  | 105.0%   | 80.9%    | 81.0%    | 0.3    | 34.0   |
| 2019-2021  | -78.0%   | 80.9%    | -125.0%  | 0.3    | 15.6   |
| 2020-2022  | -252.0%  | 85.9%    | -251.0%  | -0.9   | 4.0    |
| 2021-2023  | -315.0%  | 85.9%    | -316.0%  | -1.8   | 3.7    |
| 2022-2024  | -93.0%   | 85.9%    | -113.0%  | -1.9   | 1.6    |
| 2023-2025  | -29.0%   | 81.6%    | -93.0%   | -0.8   | 1.5    |

**Analysis:**

*   **CAGR & MDD:** CAGR was very strong in the 2017-2020 timeframe but has dropped significantly into negative territory for more recent periods. MDD(Max Drawdown) consistently remained high, indicating high volatility.
*   **Alpha:** Alpha has transitioned from strongly positive to strongly negative, indicating a significant decline in relative performance.
*   **Beta:** Beta values are unstable.
*   **Cap(B):** The market capitalization has decreased.

**2. Recent Price Action**

*   **Current Price:** $8.66
*   **Last Market Data:** {'price': 8.34, 'previousClose': 8.66, 'change': -3.7} (Indicates a 3.7% decrease)
*   **5-day Moving Average:** 8.83
*   **20-day Moving Average:** 8.44
*   **60-day Moving Average:** 7.84

**Analysis:** The stock price is below the 5-day moving average but above the 20-day and 60-day moving averages. The recent price decrease of 3.7% suggests recent negative price movement.

**3. Technical Indicators and Outlook**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 57.24 (Neutral)
*   **PPO:** 0.14 (Close to triggering a bullish signal)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (110 shares - Very Safe - MRI:0.90) (Cash Ratio: 0% on 2025-10-03)
*   **Recent (20-day) Relative Divergence Change:** -0.2 (Short-term Decline)
*   **Expected Return (%):** -8697.7 (Significant negative return expectation compared to S&P 500)

**Analysis:**

*   **MRI:** The high MRI suggests the model views the overall market as relatively safe.
*   **RSI:** An RSI of 57.24 suggests the stock is neither overbought nor oversold.
*   **PPO:** A slightly positive PPO indicates that the stock might be starting to trend upwards.
*   **Relative Divergence:** The recent negative change in relative divergence suggests short-term underperformance against the S&P 500.
*   **Last Market Data:** The 3.7% price drop should be considered when looking at the PPO.
*   **Expected Return:** The extremely negative expected return suggests significant downside risk compared to the S&P 500 over a 2+ year horizon.

**4. Recent News & Significant Events**

*   **Positive Sentiment:** Several articles mention Teladoc potentially beating earnings estimates and examining its valuation.
*   **Negative Sentiment:** Some articles highlight the stock sinking as the market gains and comparing it unfavorably to other beaten-down stocks.
*   **Competition:** An article discusses Hims & Hers, a competitor in the telehealth space.

**Analysis:** The news sentiment is mixed, with some potential positive catalysts (earnings beat) balanced by negative comparisons and competitive pressures.

**4-2. Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.64 (~Hold)
*   **Opinions:** 20
*   **Target Price (avg/high/low):** 9.22 / 12.00 / 7.00

**Analysis:** Analyst sentiment is neutral (Hold). The average target price is slightly above the current price, suggesting modest upside potential. However, the range of target prices is wide, indicating uncertainty.

**5. Recent Earnings Analysis**

| 날짜         | EPS    | 매출        |
| :----------- | :----- | :---------- |
| 2025-07-30 | -0.19 | 0.63 B$   |
| 2025-05-01 | -0.53 | 0.63 B$   |
| 2024-10-31 | -0.19 | 0.64 B$   |
| 2024-08-01 | -4.92 | 0.64 B$   |
| 2025-07-30 | -4.92 | 0.64 B$   |

**Analysis:**

*   **EPS:** EPS has been negative.
*   **Revenue:** Revenue has remained relatively stable.
*   **Duplication:** There's a duplicated line for 2025-07-30 with a large EPS loss. This may indicate a significant one-time charge in that quarter.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| :----------- | :--------- | :-------------- |
| 2025-06-30 | \$0.63B    | 69.85%          |
| 2025-03-31 | \$0.63B    | 68.73%          |
| 2024-12-31 | \$0.64B    | 70.50%          |
| 2024-09-30 | \$0.64B    | 71.94%          |
| 2024-06-30 | \$0.64B    | 70.73%          |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
| :----------- | :--------- | :-------- |
| 2025-06-30 | \$1.42B    | -2.30%    |
| 2025-03-31 | \$1.43B    | -6.52%    |
| 2024-12-31 | \$1.49B    | -3.25%    |
| 2024-09-30 | \$1.51B    | -2.21%    |
| 2024-06-30 | \$1.50B    | -55.77%   |

**Analysis:**

*   **Revenue:** Revenue is consistent.
*   **Profit Margin:** Profit margins are strong and relatively stable.
*   **Equity:** Equity has slightly decreased.
*   **ROE:** ROE is negative, indicating that the company is not generating profits from its equity. The large negative ROE in 2024-06-30 aligns with the large EPS loss reported for a similar period.

**7. Overall Analysis**

TDOC has significantly underperformed the S&P 500, and its financial performance shows mixed signals. While revenue and profit margins are decent, negative EPS and ROE indicate profitability issues. The technical indicators are somewhat neutral, but the negative expected return and recent price decline are concerning. Analyst sentiment is neutral, with a modest upside potential based on the average target price. The news is mixed, highlighting both potential positive catalysts and ongoing challenges.

**In summary, TDOC is a high-risk investment with significant challenges to overcome. While there might be short-term trading opportunities, the long-term outlook is uncertain.**
